Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes.
- Author:
Bradford S POWELL
1
;
Alexander K ANDRIANOV
;
Peter C FUSCO
Author Information
- Publication Type:Review
- Keywords: Immunologic adjuvant; Innate immunity; Toll like receptors; Pattern recognition receptors; Nalp3 protein; Alum; Aluminum hydroxide; Polymers; Chitosan; Polyphosphazene; Polyoxidonium
- MeSH: Adaptive Immunity; Adjuvants, Immunologic; Allergy and Immunology; Aluminum Hydroxide; Aluminum*; Antigen Presentation; Antigen-Presenting Cells; Bias (Epidemiology); Chitosan; Colloids; Dendritic Cells; Emulsions; Immunity, Innate; Ligands; Nanoparticles; Polymers; Receptors, Pattern Recognition; Salts*; Systems Biology; Toll-Like Receptors; Vaccines
- From:Clinical and Experimental Vaccine Research 2015;4(1):23-45
- CountryRepublic of Korea
- Language:English
- Abstract: Adjuvants improve the adaptive immune response to a vaccine antigen by modulating innate immunity or facilitating transport and presentation. The selection of an appropriate adjuvant has become vital as new vaccines trend toward narrower composition, expanded application, and improved safety. Functionally, adjuvants act directly or indirectly on antigen presenting cells (APCs) including dendritic cells (DCs) and are perceived as having molecular patterns associated either with pathogen invasion or endogenous cell damage (known as pathogen associated molecular patterns [PAMPs] and damage associated molecular patterns [DAMPs]), thereby initiating sensing and response pathways. PAMP-type adjuvants are ligands for toll-like receptors (TLRs) and can directly affect DCs to alter the strength, potency, speed, duration, bias, breadth, and scope of adaptive immunity. DAMP-type adjuvants signal via proinflammatory pathways and promote immune cell infiltration, antigen presentation, and effector cell maturation. This class of adjuvants includes mineral salts, oil emulsions, nanoparticles, and polyelectrolytes and comprises colloids and molecular assemblies exhibiting complex, heterogeneous structures. Today innovation in adjuvant technology is driven by rapidly expanding knowledge in immunology, cross-fertilization from other areas including systems biology and materials sciences, and regulatory requirements for quality, safety, efficacy and understanding as part of the vaccine product. Standardizations will aid efforts to better define and compare the structure, function and safety of adjuvants. This article briefly surveys the genesis of adjuvant technology and then re-examines polyionic macromolecules and polyelectrolyte materials, adjuvants currently not known to employ TLR. Specific updates are provided for aluminum-based formulations and polyelectrolytes as examples of improvements to the oldest and emerging classes of vaccine adjuvants in use.
